Stay updated on Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded posted results data including incidence of dose-limiting toxicities, 18-month overall survival, and adverse events with time-to-event endpoints, and updated results reporting dates. Linked or updated study documents (protocol/consent forms) accompany the results.SummaryDifference2%

- Check25 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check40 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no substantive content changes are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedThe change consists only of a version revision tag, updating from v3.4.0 to v3.4.1, with no changes to study content or page functionality. To avoid being alert by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this appears to be a minor backend update with no visible changes to study content or navigation.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.